NRXP Stock Price, NRx Pharmaceuticals, . Quote, Chart

Market Summary

USD2.20-0.38

Delayedas of 01 May 2024, 12:17 pm

-14.73%

NRXP Stock Price

View Fullscreen

NRXP RSI Chart

NRXP Valuation

Market Cap

27.2M

Price/Earnings (Trailing)

-0.9

Price/Sales (Trailing)

55.13

EV/EBITDA

-0.74

Price/Free Cashflow

-1.26

NRXP Price/Sales (Trailing)

NRXP Profitability

EBT Margin

-8047.37%

Return on Equity

256.97%

Return on Assets

-412.17%

Free Cashflow Yield

-79.53%

NRXP Fundamentals

NRXP Revenue

Revenue (TTM)

494.0K

NRXP Earnings

Earnings (TTM)

-30.1M

Earnings Growth (Yr)

57.7%

Earnings Growth (Qtr)

28.54%

Breaking Down NRXP Revenue

52 Week Range

2.29

(Low)(High)

Last 7 days

-15.4%

Last 30 days

-45.3%

Last 90 days

-30.3%

Trailing 12 Months

-54.8%

How does NRXP drawdown profile look like?

NRXP Financial Health

Current Ratio

0.36

NRXP Investor Care

Shares Dilution (1Y)

50.13%

Diluted EPS (TTM)

-4.95

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	310.3K	371.5K	432.8K	494.0K
2022	2.5M	1.4M	0	249.0K
2021	0	0	0	3.7M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of NRx Pharmaceuticals, Inc.

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Aug 30, 2023	gorovitz aaron	bought	11,196	0.3199	35,000	-
Aug 30, 2023	hurvitz chaim	bought	20,125	0.2875	70,000	-
Aug 23, 2023	javitt jonathan c	bought	33,000	0.33	100,000	chief scientist
Aug 22, 2023	javitt jonathan c	bought	64,400	0.322	200,000	chief scientist
Dec 16, 2022	van voorhees seth	bought	33,000	1.1	30,000	chief financial officer
Dec 16, 2022	willard stephen h	bought	58,500	1.17	50,000	chief executive officer
Dec 14, 2022	javitt jonathan c	gifted	-	-	-300,000	-
Dec 07, 2022	javitt jonathan c	sold	-400,000	1.00	-400,000	-
Nov 30, 2022	javitt daniel c.	sold	-12,700	1.5046	-8,441	-
Nov 29, 2022	javitt daniel c.	sold	-20,651	1.5041	-13,730	-

Which funds bought or sold NRXP recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	SIMPLEX TRADING, LLC	new	-	-	-	-%
Apr 25, 2024	Bank of New York Mellon Corp	unchanged	-	121	4,780	-%
Apr 23, 2024	United Asset Strategies, Inc.	unchanged	-	218	8,636	-%
Apr 19, 2024	Cutler Group LLC / CA	unchanged	-	-	1,000	-%
Mar 26, 2024	HighPoint Advisor Group LLC	new	-	23,000	23,000	-%
Mar 11, 2024	VANGUARD GROUP INC	reduced	-0.37	287,627	664,781	-%
Feb 14, 2024	TWO SIGMA SECURITIES, LLC	sold off	-100	-13,845	-	-%
Feb 14, 2024	Royal Bank of Canada	reduced	-11.86	25,000	69,000	-%
Feb 14, 2024	BRIDGEWAY CAPITAL MANAGEMENT, LLC	reduced	-23.65	14,660	56,442	-%

Are Funds Buying or Selling NRXP?

Are funds buying NRXP calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own NRXP

No. of Funds

Unveiling NRx Pharmaceuticals, Inc.'s Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Sep 13, 2022	javitt daniel c.	14.6%	9,872,901	SC 13D
Jun 17, 2022	javitt jonathan c	22.3%	14,868,329	SC 13D/A
Jun 03, 2022	javitt jonathan c	22.3%	14,868,329	SC 13D

Recent SEC filings of NRx Pharmaceuticals, Inc.

View All Filings

Date Filed	Form Type	Document
Apr 30, 2024	8-K	Current Report
Apr 29, 2024	10-K/A	Annual Report
Apr 19, 2024	424B5	Prospectus Filed
Apr 19, 2024	8-K	Current Report
Apr 18, 2024	424B5	Prospectus Filed
Apr 15, 2024	424B3	Prospectus Filed
Apr 15, 2024	424B3	Prospectus Filed
Apr 15, 2024	8-K	Current Report
Apr 02, 2024	8-K	Current Report
Mar 29, 2024	10-K	Annual Report

Peers (Alternatives to NRx Pharmaceuticals, Inc.)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	42.1B	6.8B	3.52%	-17.31%	-8.94	6.15	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.1B	1.8B	-3.68%	-28.69%	-41.18	9.92	76.23%	61.08%
BMRN	15.3B	2.5B	-7.53%	-16.73%	74.64	6.2	13.74%	186.89%
INCY	11.7B	3.8B	-8.64%	-30.91%	15.68	3.1	8.58%	129.81%
MID-CAP
APLS	5.3B	396.6M	-24.84%	-46.72%	-10.08	13.44	425.83%	18.94%
BBIO	4.5B	-	-17.14%	78.66%	-6.9	60.35	54.84%	-34.79%
AXSM	3.5B	270.6M	-7.57%	4.22%	-14.61	12.91	440.80%	-27.84%
ARWR	2.8B	240.7M	-20.91%	-36.67%	-9.44	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-9.63%	-23.17%	-44.93	3.79	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-5.58%	-11.16%	24.84	4.45	85.90%	-14.05%
NVAX	606.0M	983.7M	-9.41%	-43.91%	-1.11	0.62	-50.36%	17.16%
CRBP	388.7M	881.7K	-5.61%	336.79%	-8.71	466.16	-77.61%	-5.33%
INO	267.6M	4.9M	-17.51%	25.55%	-1.98	54.99	-54.97%	51.71%
IBIO	6.0M	2.1M	-57.88%	56.88%	-0.22	2.14	-13.45%	66.37%

NRx Pharmaceuticals, Inc. News

Latest updates

NRx Pharmaceuticals, Inc. Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q2	2022Q1	2021Q4	2021Q3
Revenue	-	-	-	2,168,000	351,000	175,500	-	2,020,000	2,844,500	3,669,000
Operating Expenses	-24.1%	4,406,000	5,808,000	8,188,000	9,435,000	9,888,500	9,600,000	15,705,000	52,975,000	20,099,000
S&GA Expenses	-24.9%	1,872,000	2,494,000	4,065,000	5,785,000	5,432,000	6,642,000	10,222,000	51,641,000	13,823,000
R&D Expenses	-23.5%	2,534,000	3,314,000	3,873,000	3,650,000	4,456,500	2,958,000	5,483,000	6,413,000	6,276,000
EBITDA Margin	12.7%	-80.22	-91.84	-106	-128	-159	-66.99	-36.79	-25.36	-
Interest Expenses	100.0%	80,000	40,000	-	-	-	-	3,000	2,500	5,000
Income Taxes	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-	-	-	-	-	-	-	-	-30,407,181	-37,049,331
EBT Margin	12.4%	-80.47	-91.86	-107	-128	-159	-67.00	-36.80	-25.36	-
Net Income	28.5%	-4,332,000	-6,062,000	-8,717,000	-11,039,000	-10,241,000	-6,982,000	-13,448,000	-30,407,500	-37,049,000
Net Income Margin	26.8%	-61.03	-83.33	-105	-120	-159	-63.27	-32.04	-25.36	-
Free Cashflow	30.1%	-3,192,000	-4,564,000	-7,812,000	-6,089,000	-8,318,000	-14,791,000	-10,380,000	-11,280,000	-12,014,000

Balance Sheet

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Balance Sheet																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-44.2%	7,315	13,110	19,809	21,780	25,816	24,824	32,433	43,601	32,729	45,250	18,547	13,572	2,941	6,032	6,277	6,273	23,979	41,685	50,103	71,708	70,796
Current Assets	-47.4%	6,884	13,089	19,788	21,756	25,795	24,801	32,414	43,584	32,714	45,234	18,534	13,562	2,930	97.00	37.00	81.00	975	208	41.00	51.00	30.00
Cash Equivalents	-48.4%	4,595	8,902	14,969	16,506	20,054	18,249	24,548	40,202	27,605	38,884	13,386	13,271	1,859	1,288	996	272	877	194	1.00	2.00	621
Liabilities	-1.4%	19,048	19,327	22,617	22,064	18,407	8,042	7,081	11,912	11,923	36,769	58,314	7,189	46,712	2,831	2,651	2,497	5,837	2,434	2,108	1,981	1,257
Current Liabilities	-1.4%	19,048	19,327	22,617	22,064	15,585	-	-	-	11,923	36,769	57,802	6,679	46,164	379	297	316	2,375	642	521	494	567
Shareholder's Equity	-Infinity%	-11,733	-	-	-	7,409	16,782	25,352	31,689	20,806	8,482	-	6,391	2,114	3,201	3,626	3,776	5,000	5,000	5,000	5,000	1.00
Retained Earnings	-1.7%	-253,147	-248,815	-242,753	-234,036	-222,997	-212,756	-203,673	-196,691	-183,243	-152,835	-115,786	-115,668	-90,179	367	493	643	-38,402	384	325	149	683*
Additional Paid-In Capital	-0.5%	241,330	242,533	239,887	233,576	230,339	229,470	228,958	228,313	203,990	161,262	75,970	122,037	46,366	2,831	3,130	3,130	33,539	4,613	4,672	4,848	5,036
Shares Outstanding	0%	8,392	8,392	8,039	7,031	6,644	6,645	6,573	6,367	5,881	5,174	4,173	-	-	-	-	-	-	-	-	-	-
Float	-	-	-	29,700	-	34,952,532,000	-	40,584,788,400	-	-	-	187,300	-	-	-	6,100	-	-	-	50,300	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	30.1%	-3,192	-4,564	-7,812	-6,089	-8,318	-6,266	-14,791	-10,380	-11,280	-12,014	-11,394	-3,015	-406	-1,130	104	-832	-5,011	-52.31	-180	-297	-70.88
Share Based Compensation	-442.7%	-1,203	351	544	695	766	541	987	1,334	1,570	1,560	4,283	372	357	191	93.00	89.00	-	-	-	-	-
Cashflow From Investing	150.0%	1.00	-2.00	2.00	-4.00	1.00	-5.00	-3.00	-3.00	-	-4.00	-3.00	-	-26,211	306	-23.22	25,926	-30,606	8,931	22,179	-508	610
Cashflow From Financing	25.6%	-1,116	-1,501	6,273	2,545	10,122	-28.00	-860	22,980	1.00	37,516	11,512	14,427	980	1,422	620	227	35,691	-8,686	-21,999	797	690
Buy Backs	-	-	-	-	-	-	-	-	-	-	-	-	-	-	299	-	25,998	-30,990	8,891	22,099	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

NRXP Income Statement

2023-12-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Operating expenses:
Research and development expenses	$ 13,371	$ 17,027
General and administrative	14,216	27,308
Settlement expense	250
Total operating expenses	27,837	44,335
Loss from operations	(27,837)	(44,335)
Other (income) expenses:
Interest income	(494)	(249)
Interest expense	120
Change in fair value of convertible note payable	2,707	505
Change in fair value of warrant liabilities	(20)	(255)
Change in fair value of earnout cash liability		(4,582)
Total other (income) expenses	2,313	(4,581)
Net loss	(30,150)	(39,754)
Deemed Dividend - Warrants	(9)
Net loss attributable to common stockholders	(30,159)	(39,754)
Change in fair value of convertible note attributed to credit risk	(3)
Other comprehensive loss	$ (30,153)	$ (39,754)
Net loss per share:
Basic	$ (0.40)	$ (0.60)
Weighted average common shares outstanding:
Basic	75,761,763	65,766,786

NRXP Balance Sheet

2023-12-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 4,595	$ 20,054
Prepaid expenses and other current assets	2,289	5,741
Total current assets	6,884	25,795
Other assets	431	21
Total assets	7,315	25,816
Current liabilities:
Accounts payable	4,632	2,076
Accrued and other current liabilities	4,714	4,855
Accrued clinical site costs	524	914
Convertible note payable and accrued interest - short term	9,161	7,703
Warrant liabilities	17	37
Total current liabilities	19,048	15,585
Convertible note payable and accrued interest - long term		2,822
Total liabilities	19,048	18,407
Common stock, $0.001 par value, 500,000,000 shares authorized; 83,919,554 and 66,442,989 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively	84	67
Additional paid-in capital	241,330	230,339
Accumulated other comprehensive loss	(3)
Accumulated deficit	(253,147)	(222,997)
Total stockholders' (deficit) equity	(11,733)	7,409
Total liabilities and stockholders' (deficit) equity	7,315	$ 25,816
Series A Convertible Preferred Stock
Current liabilities:
Preferred stock, $0.001 par value, 50,000,000 shares authorized; Series A convertible preferred stock, $0.001 par value, 12,000,000 shares authorized; 3,000,000 and 0 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively	$ 3

About NRx Pharmaceuticals, Inc.

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics that is in phase IIb/III clinical trials for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.

0

CEO	Mr. Stephen H. Willard Esq.
WEBSITE	nrxpharma.com
INDUSTRY	Biotechnology

NRx Pharmaceuticals, Inc. Frequently Asked Questions

What is the ticker symbol for NRx Pharmaceuticals, Inc.? What does NRXP stand for in stocks?

NRXP is the stock ticker symbol of NRx Pharmaceuticals, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of NRx Pharmaceuticals, Inc. (NRXP)?

As of Tue Apr 30 2024, market cap of NRx Pharmaceuticals, Inc. is 27.23 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of NRXP stock?

You can check NRXP's fair value in chart for subscribers.

What is the fair value of NRXP stock?

You can check NRXP's fair value in chart for subscribers. The fair value of NRx Pharmaceuticals, Inc. is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of NRx Pharmaceuticals, Inc. is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for NRXP so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is NRx Pharmaceuticals, Inc. a good stock to buy?

The fair value guage provides a quick view whether NRXP is over valued or under valued. Whether NRx Pharmaceuticals, Inc. is cheap or expensive depends on the assumptions which impact NRx Pharmaceuticals, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for NRXP.

What is NRx Pharmaceuticals, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 30 2024, NRXP's PE ratio (Price to Earnings) is -0.9 and Price to Sales (PS) ratio is 55.13. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. NRXP PE ratio will change depending on the future growth rate expectations of investors.